
Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …

Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

